Evidence map›Paper›PMID 30076547›Full record

ArticleAnnals of intensive care2018

Characteristics and outcome of patients with newly diagnosed advanced or metastatic lung cancer admitted to intensive care units (ICUs).

C Barth, M Soares, A C Toffart, J F Timsit, G Burghi, C Irrazabal, N Pattison, E Tobar, B F Almeida, U V Silva and 15 more

Abstract read
In one paragraph

Article in Annals of intensive care, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Observational
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Observational
  12. Critically ill patients with cancer: A clinical perspective.World journal of clinical oncology · 2020
    Review
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

C BarthMedical ICU, AP-HP, Hôpital Saint-Louis, 1 Avenue Claude Vellefaux, 75010, Paris, France.
M SoaresPost-Graduation Program, Instituto Nacional de Câncer, Rio de Janeiro Department of Clinical Research, D'Or Institute for Research and Education, Rio de Janeiro, Brazil.
A C ToffartInserm, u 823, Institut A Bonniot, Grenoble, France.
J F TimsitMedical ICU, Hôpital Bichat-Claude Bernard, Paris, France.
G BurghiICU, Hospital Maciel, Montevideo, Uruguay.
C IrrazabalICU, Instituto Medico Especializado Alexander Fleming, Buenos Aires, Argentina.
N PattisonICU, Royal Brompton NHS Foundation Trust, London ICU, Royal Marsden Hospital, London, UK.
E TobarICU, Hospital Clinico Universidad de Chile, Santiago, Chile.
B F AlmeidaICU, Hospital A. C. Camargo, São Paulo, Brazil.
U V SilvaICU, Fundação Pio XII-Hospital do Câncer de Barretos, Barretos, Brazil.
L C AzevedoICU, Hospital Sírio Libanês, São Paulo, Brazil.
A RabbatThoracic ICU, Hôpital Cochin, Paris, France.
C LamerICU, Institut Mutualiste Montsouris, Paris, France.
A ParrotMedical ICU, Hôpital Tenon, Paris, France.
V C Souza-DantasICU, Instituto Nacional de Câncer-Hospital do Câncer I, Rio de Janeiro, Brazil.
F WalletMedical-Surgical ICU, Hospices Civils de Lyon Centre Hospitalier Lyon Sud, Lyon, France.
F BlotICU, Institut Gustave Roussy, Villejuif, France.
G BourdinMedical ICU, Hôpital de la Croix-Rousse, Lyon, France.
C PirasICU, Vitória Apart Hospital, Vitória, Brazil.
J DelemazureMedical ICU, Groupe Hospitalier Pitié Salpêtrière, Paris, France.
M DurandSurgical ICU, Hôpital A. Michallon Chu de Grenoble, Grenoble, France.
J SalluhPost-Graduation Program, Instituto Nacional de Câncer, Rio de Janeiro Department of Clinical Research, D'Or Institute for Research and Education, Rio de Janeiro, Brazil.
E AzoulayMedical ICU, AP-HP, Hôpital Saint-Louis, 1 Avenue Claude Vellefaux, 75010, Paris, France.
Virginie LemialeMedical ICU, AP-HP, Hôpital Saint-Louis, 1 Avenue Claude Vellefaux, 75010, Paris, France. virginie.lemiale@aphp.fr.
Lung Cancer in Critical Care (LUCCA) Study Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough patients with advanced or metastatic lung cancer have poor prognosis, admission to the ICU for management of life-threatening complications has increased over the years. Patients with newly diagnosed lung cancer appear as good candidates for ICU admission, but more robust information to assist decisions is lacking. The aim of our study was to evaluate the prognosis of newly diagnosed unresectable lung cancer patients.

methodsA retrospective multicentric study analyzed the outcome of patients admitted to the ICU with a newly diagnosed lung cancer (diagnosis within the month) between 2010 and 2013.

resultsOut of the 100 patients, 30 had small cell lung cancer (SCLC) and 70 had non-small cell lung cancer. (Thirty patients had already been treated with oncologic treatments.) Mechanical ventilation (MV) was performed for 81 patients. Seventeen patients received emergency chemotherapy during their ICU stay. ICU, hospital, 3- and 6-month mortality were, respectively, 47, 60, 67 and 71%. Hospital mortality was 60% when invasive MV was used alone, 71% when MV and vasopressors were needed and 83% when MV, vasopressors and hemodialysis were required. In multivariate analysis, hospital mortality was associated with metastatic disease (OR 4.22 [1.4-12.4]; p = 0.008), need for invasive MV (OR 4.20 [1.11-16.2]; p = 0.030), while chemotherapy in ICU was associated with survival (OR 0.23, [0.07-0.81]; p = 0.020).

conclusionThis study shows that ICU management can be appropriate for selected newly diagnosed patients with advanced lung cancer, and chemotherapy might improve outcome for patients with SCLC admitted for cancer-related complications. Nevertheless, tumors' characteristics, numbers and types of organ dysfunction should be taken into account in the decisional process before admitting these patients in ICU.

Indexed as

ChemotherapyIntensive careLung cancerMetastaticOutcome

Identifiers

PMID30076547
PMCPMC6076209

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.